373 related articles for article (PubMed ID: 30357021)
21. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
22. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
23. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma.
Li H
Dig Liver Dis; 2022 May; 54(5):598-613. PubMed ID: 34344577
[TBL] [Abstract][Full Text] [Related]
24. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.
Deng L; He K; Pan Y; Wang H; Luo Y; Xia Q
Int J Med Sci; 2021; 18(10):2109-2116. PubMed ID: 33859517
[TBL] [Abstract][Full Text] [Related]
25. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Petrizzo A; Buonaguro L
Cancer Lett; 2020 Mar; 473():25-32. PubMed ID: 31875523
[TBL] [Abstract][Full Text] [Related]
26. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
27. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
28. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
29. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma.
Sheppard S; Guedes J; Mroz A; Zavitsanou AM; Kudo H; Rothery SM; Angelopoulos P; Goldin R; Guerra N
Nat Commun; 2017 Jan; 8():13930. PubMed ID: 28128200
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
32. Road to stemness in hepatocellular carcinoma.
Flores-Téllez TN; Villa-Treviño S; Piña-Vázquez C
World J Gastroenterol; 2017 Oct; 23(37):6750-6776. PubMed ID: 29085221
[TBL] [Abstract][Full Text] [Related]
33. Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
Liang YJ; Teng W; Chen CL; Sun CP; Teng RD; Huang YH; Liang KH; Chen YW; Lin CC; Su CW; Tao MH; Wu JC
Hepatology; 2021 Aug; 74(2):641-655. PubMed ID: 33675094
[TBL] [Abstract][Full Text] [Related]
34. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
[TBL] [Abstract][Full Text] [Related]
35. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
36. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (Review).
Pan JH; Zhou H; Zhao XX; Ding H; Li W; Qin L; Pan YL
Int J Mol Med; 2018 Apr; 41(4):1809-1816. PubMed ID: 29328436
[TBL] [Abstract][Full Text] [Related]
37. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
Hou J; Zhang H; Sun B; Karin M
J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
[TBL] [Abstract][Full Text] [Related]
38. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
[TBL] [Abstract][Full Text] [Related]
39. Immune suppression in chronic hepatitis B infection associated liver disease: A review.
Li TY; Yang Y; Zhou G; Tu ZK
World J Gastroenterol; 2019 Jul; 25(27):3527-3537. PubMed ID: 31367154
[TBL] [Abstract][Full Text] [Related]
40. Group-2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression.
Xu X; Ye L; Zhang Q; Shen H; Li S; Zhang X; Ye M; Liang T
Hepatology; 2021 Nov; 74(5):2526-2543. PubMed ID: 33829508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]